angiotensin ii has been researched along with Hyperlipoproteinemia Type II in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Brinck, J; Ekholm, M; Jörneskog, G; Kahan, T; Wallén, HN | 1 |
| Balakrishnan, A; Cassis, LA; Charnigo, R; Chen, X; Daugherty, A; Howatt, DA; Moorleghen, JJ; Morris, AJ; Rateri, DL | 1 |
| Brinck, J; Ekholm, M; Jörneskog, G; Kahan, T; Wallén, NH | 1 |
| Chen, Y; Chen, YE; Fan, J; Kang, D; Li, S; Liu, E; Niimi, M; Ning, B; Shiomi, M; Wang, YN; Wang, Z; Waqar, AB; Yu, Q; Zhang, J | 1 |
| Bunker, AK; Laughlin, MH | 1 |
| Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Nishida, K; Takeshita, A; Usui, M; Zhao, Q | 1 |
| Ferrannini, E; Santini, E; Solini, A | 1 |
| Cheng, C; Daemen, MJ; de Crom, R; Grosveld, F; Krams, R; Tempel, D; van der Baan, A; van Haperen, R | 1 |
| Anedda, S; Maxia, P; Pintus, P; Pintus, S | 1 |
1 trial(s) available for angiotensin ii and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Haemostatic and inflammatory alterations in familial hypercholesterolaemia, and the impact of angiotensin II infusion.
Topics: Adult; Angiotensin II; Antifibrinolytic Agents; Biomarkers; Blood Pressure; Calibration; Case-Control Studies; Demography; Female; Fibrinolysin; Heart Rate; Hemostasis; Humans; Hyperlipoproteinemia Type II; Inflammation; Interleukin-6; Leukocytes; Male; Peptide Fragments; Placebos; Plasminogen Activator Inhibitor 1; Prothrombin | 2015 |
8 other study(ies) available for angiotensin ii and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Altered Vascular Reactivity to Circulating Angiotensin II in Familial Hypercholesterolemia.
Topics: Adult; Angiotensin II; Arterial Pressure; Brachial Artery; Case-Control Studies; Female; Forearm; Humans; Hyperlipoproteinemia Type II; Infusions, Intravenous; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Skin; Time Factors; Vasodilation | 2021 |
Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic mice.
Topics: Amlodipine; Angiotensin II; Animals; Aortic Aneurysm; Atherosclerosis; Hyperlipoproteinemia Type II; Male; Mice; Mice, Knockout; Receptors, LDL | 2013 |
Angiotensin II Destabilizes Coronary Plaques in Watanabe Heritable Hyperlipidemic Rabbits.
Topics: Angiotensin II; Animals; Coronary Artery Disease; Coronary Vessels; Disease Models, Animal; Genetic Predisposition to Disease; Heredity; Hyperlipoproteinemia Type II; Infusion Pumps, Implantable; Infusions, Subcutaneous; Myocardial Infarction; Phenotype; Plaque, Atherosclerotic; Rabbits; Time Factors | 2016 |
Influence of exercise and perivascular adipose tissue on coronary artery vasomotor function in a familial hypercholesterolemic porcine atherosclerosis model.
Topics: Adipose Tissue; Angiotensin II; Animals; Atherosclerosis; Bradykinin; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Hyperlipoproteinemia Type II; Male; Nitroprusside; Physical Exertion; Sedentary Behavior; Swine; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2010 |
Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Chemokine CCL2; Chemokines; Cytokines; Disease Progression; Gene Expression Regulation; Gene Targeting; Humans; Hyperlipoproteinemia Type II; Imidazoles; Inflammation; Inflammation Mediators; Injections, Intramuscular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Olmesartan Medoxomil; Random Allocation; Recombinant Fusion Proteins; Sequence Deletion; Single-Blind Method; Tetrazoles | 2004 |
Enhanced angiotensin II-mediated effects in fibroblasts of patients with familial hypercholesterolemia.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biphenyl Compounds; Calcium; Case-Control Studies; Cell Proliferation; Cells, Cultured; Cholesterol, LDL; Dose-Response Relationship, Drug; Endothelin-1; Female; Fibroblasts; Heterozygote; Humans; Hyperlipoproteinemia Type II; Irbesartan; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Middle Aged; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta | 2005 |
Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress.
Topics: Angiotensin II; Animals; Apolipoproteins E; Atherosclerosis; Blood Flow Velocity; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Diet, Atherogenic; Hemorheology; Hemorrhage; Hyperlipoproteinemia Type II; Hyperplasia; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Phenotype; Prostheses and Implants; Shear Strength; Stress, Mechanical; Tunica Intima; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2006 |
Use of losartan in FH patients during treatment with DSC-LDL apheresis.
Topics: Angiotensin II; Blood Component Removal; Dextran Sulfate; Humans; Hyperlipoproteinemia Type II; Hypotension; Lipoproteins, LDL; Losartan | 1997 |